Pharmacogenetics and adverse drug reports: Insights from a United Kingdom national pharmacovigilance database.

ABSTRACT:

Background

Adverse drug reactions (ADRs) harm patients and are costly for healthcare systems. Genetic variation contributes to variability in medication response and prospective knowledge of these variants can decrease risk of ADRs, as shown in the PREPARE trial. Reduction in ADRs would affect only those reactions to drugs contained in well-validated pharmacogene-drug pairs. The scope of ADRs represented by these drugs on a population scale is unclear. The objective of this study was to characterize the pharmacogene-drug-associated ADR reporting landscape from a national regulatory pharmacovigilance dataset to elucidate the scale of potential ADR mitigation by pharmacogenomics (PGx) implementation.

Methods and findings

All publicly available Yellow Card ADR reports to the Un

SUBMITTER: Magavern EF 

PROVIDER: S-EPMC11949333 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature